L. Toto, Pasquale Viggiano, Alberto Quarta, M. Grassi, Chiara De Nicola, R. Aloia, Rossella D’Aloisio, Giacomo Boscia, Francesco Boscia, A. Porreca, M. Di Nicola, M. Savastano, Rodolfo Mastropasqua
{"title":"Pro Re Nata 方案与抗血管内皮生长因子对 3 型黄斑新生血管的影响--长期疗效。","authors":"L. Toto, Pasquale Viggiano, Alberto Quarta, M. Grassi, Chiara De Nicola, R. Aloia, Rossella D’Aloisio, Giacomo Boscia, Francesco Boscia, A. Porreca, M. Di Nicola, M. Savastano, Rodolfo Mastropasqua","doi":"10.1159/000538441","DOIUrl":null,"url":null,"abstract":"(348 words) Introduction: The purpose of this study is to investigate long-term outcomes of intravitreal injections (IVI) of anti-vascular endothelial growth factor (VEGF) in neovascular age-related macular degeneration (nAMD) with type 3 macular neovascularization (MNV).\n\n\nMETHODS\nThis retrospective study included 19 eyes of 17 patients with nAMD and type 3 MNV treated with anti-VEGF IVI with a loading dose and PRN regimen. Best corrected visual acuity (BCVA), central macular thickness (CMT), presence of macular intraretinal fluid (IRF) and subretinal fluid (SRF), flow area (FA), subfoveal choroidal thickness (CT) and macular atrophy (MA) were assessed at baseline (T0) and during follow up (T1, post loading phase; T2, one year; T3, two years, T4>2 years). The correlations between MA at the last follow-up and standard deviation (SD) values of CMT and CT during follow-up were assessed. The influence of the number of injections on the change in MA over time was also analysed. MA differences at T4 were assessed for pseudodrusen presence.\n\n\nRESULTS\nBCVA improved significantly during follow-up (p=0.013) particularly increasing from baseline to post loading phase and then did not modify significantly thereafter. CMT significantly reduced from T0 to T1 and remained stable during follow-up (p = <0.001). MNV flow area showed a trend toward increase in the post loading phase that was not statistically significant (p=0.082) and CT decreased significantly during follow-up (p<0.001). MA changed significantly during follow-up (p<0.001) with significant increase from T0 to T3 and from T0 to T4 (p < 0.010). Cochrane Armitage test for trend showed a significant reduction (p=0.001) of macular IRF and SRF during follow-up. MA at T4 showed a significant positive correlation with SD (standard deviation) values of CMT (p=0.040) and CT (p=0.020). Indeed, the number of injections did not influence the change over time of MA (p=0.709). MA at T4 was not statistically significantly different between patients with pseudodrusen at baseline (p=0.497).\n\n\nCONCLUSIONS\nIntravitreal anti-VEGF injections with PRN regimen in MNV type 3 showed functional and anatomical benefits. Variations of retinal thickness and choroidal thickness during treatment were related to MA modification over time.","PeriodicalId":19662,"journal":{"name":"Ophthalmic Research","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Pro Re Nata regimen with anti-VEGF on Type 3 Macular Neovascularization - Long term outcomes.\",\"authors\":\"L. Toto, Pasquale Viggiano, Alberto Quarta, M. Grassi, Chiara De Nicola, R. Aloia, Rossella D’Aloisio, Giacomo Boscia, Francesco Boscia, A. Porreca, M. Di Nicola, M. Savastano, Rodolfo Mastropasqua\",\"doi\":\"10.1159/000538441\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"(348 words) Introduction: The purpose of this study is to investigate long-term outcomes of intravitreal injections (IVI) of anti-vascular endothelial growth factor (VEGF) in neovascular age-related macular degeneration (nAMD) with type 3 macular neovascularization (MNV).\\n\\n\\nMETHODS\\nThis retrospective study included 19 eyes of 17 patients with nAMD and type 3 MNV treated with anti-VEGF IVI with a loading dose and PRN regimen. Best corrected visual acuity (BCVA), central macular thickness (CMT), presence of macular intraretinal fluid (IRF) and subretinal fluid (SRF), flow area (FA), subfoveal choroidal thickness (CT) and macular atrophy (MA) were assessed at baseline (T0) and during follow up (T1, post loading phase; T2, one year; T3, two years, T4>2 years). The correlations between MA at the last follow-up and standard deviation (SD) values of CMT and CT during follow-up were assessed. The influence of the number of injections on the change in MA over time was also analysed. MA differences at T4 were assessed for pseudodrusen presence.\\n\\n\\nRESULTS\\nBCVA improved significantly during follow-up (p=0.013) particularly increasing from baseline to post loading phase and then did not modify significantly thereafter. CMT significantly reduced from T0 to T1 and remained stable during follow-up (p = <0.001). MNV flow area showed a trend toward increase in the post loading phase that was not statistically significant (p=0.082) and CT decreased significantly during follow-up (p<0.001). MA changed significantly during follow-up (p<0.001) with significant increase from T0 to T3 and from T0 to T4 (p < 0.010). Cochrane Armitage test for trend showed a significant reduction (p=0.001) of macular IRF and SRF during follow-up. MA at T4 showed a significant positive correlation with SD (standard deviation) values of CMT (p=0.040) and CT (p=0.020). Indeed, the number of injections did not influence the change over time of MA (p=0.709). MA at T4 was not statistically significantly different between patients with pseudodrusen at baseline (p=0.497).\\n\\n\\nCONCLUSIONS\\nIntravitreal anti-VEGF injections with PRN regimen in MNV type 3 showed functional and anatomical benefits. Variations of retinal thickness and choroidal thickness during treatment were related to MA modification over time.\",\"PeriodicalId\":19662,\"journal\":{\"name\":\"Ophthalmic Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmic Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000538441\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538441","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
(348 words) Introduction:本研究旨在探讨抗血管内皮生长因子(VEGF)玻璃体内注射(IVI)对伴有3型黄斑新生血管(MNV)的新生血管性年龄相关性黄斑变性(nAMD)患者的长期疗效。在基线(T0)和随访期间(T1,负荷后阶段;T2,一年;T3,两年;T4>2年)评估了最佳矫正视力(BCVA)、黄斑中心厚度(CMT)、黄斑视网膜内积液(IRF)和视网膜下积液(SRF)、血流面积(FA)、眼底脉络膜厚度(CT)和黄斑萎缩(MA)。评估了最后一次随访时的 MA 值与随访期间 CMT 和 CT 标准差 (SD) 值之间的相关性。还分析了注射次数对 MA 随时间变化的影响。结果BCVA在随访期间明显改善(p=0.013),尤其是从基线到负荷后阶段,此后没有明显变化。CMT 从 T0 到 T1 显著减少,并在随访期间保持稳定(p = <0.001)。MNV 血流面积在加载后阶段呈上升趋势,但无统计学意义(p=0.082),CT 在随访期间显著下降(p<0.001)。MA 在随访期间有明显变化(p<0.001),从 T0 到 T3 以及从 T0 到 T4 有明显增加(p<0.010)。Cochrane Armitage 趋势检验显示,随访期间黄斑 IRF 和 SRF 明显降低(p=0.001)。T4的MA与CMT(P=0.040)和CT(P=0.020)的SD(标准差)值呈显著正相关。事实上,注射次数并不影响 MA 随时间的变化(p=0.709)。结论在 MNV 3 型患者中采用 PRN 方案进行玻璃体内抗 VEGF 注射显示出功能和解剖上的益处。治疗期间视网膜厚度和脉络膜厚度的变化与 MA 随时间的变化有关。
Effect of Pro Re Nata regimen with anti-VEGF on Type 3 Macular Neovascularization - Long term outcomes.
(348 words) Introduction: The purpose of this study is to investigate long-term outcomes of intravitreal injections (IVI) of anti-vascular endothelial growth factor (VEGF) in neovascular age-related macular degeneration (nAMD) with type 3 macular neovascularization (MNV).
METHODS
This retrospective study included 19 eyes of 17 patients with nAMD and type 3 MNV treated with anti-VEGF IVI with a loading dose and PRN regimen. Best corrected visual acuity (BCVA), central macular thickness (CMT), presence of macular intraretinal fluid (IRF) and subretinal fluid (SRF), flow area (FA), subfoveal choroidal thickness (CT) and macular atrophy (MA) were assessed at baseline (T0) and during follow up (T1, post loading phase; T2, one year; T3, two years, T4>2 years). The correlations between MA at the last follow-up and standard deviation (SD) values of CMT and CT during follow-up were assessed. The influence of the number of injections on the change in MA over time was also analysed. MA differences at T4 were assessed for pseudodrusen presence.
RESULTS
BCVA improved significantly during follow-up (p=0.013) particularly increasing from baseline to post loading phase and then did not modify significantly thereafter. CMT significantly reduced from T0 to T1 and remained stable during follow-up (p = <0.001). MNV flow area showed a trend toward increase in the post loading phase that was not statistically significant (p=0.082) and CT decreased significantly during follow-up (p<0.001). MA changed significantly during follow-up (p<0.001) with significant increase from T0 to T3 and from T0 to T4 (p < 0.010). Cochrane Armitage test for trend showed a significant reduction (p=0.001) of macular IRF and SRF during follow-up. MA at T4 showed a significant positive correlation with SD (standard deviation) values of CMT (p=0.040) and CT (p=0.020). Indeed, the number of injections did not influence the change over time of MA (p=0.709). MA at T4 was not statistically significantly different between patients with pseudodrusen at baseline (p=0.497).
CONCLUSIONS
Intravitreal anti-VEGF injections with PRN regimen in MNV type 3 showed functional and anatomical benefits. Variations of retinal thickness and choroidal thickness during treatment were related to MA modification over time.
期刊介绍:
''Ophthalmic Research'' features original papers and reviews reporting on translational and clinical studies. Authors from throughout the world cover research topics on every field in connection with physical, physiologic, pharmacological, biochemical and molecular biological aspects of ophthalmology. This journal also aims to provide a record of international clinical research for both researchers and clinicians in ophthalmology. Finally, the transfer of information from fundamental research to clinical research and clinical practice is particularly welcome.